Nivolumab/pembrolizumabTuberculosis: 2 case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2019年 / 1742卷 / 1期

关键词：

D O I：

10.1007/s40278-019-58634-7

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：176 / 176

相关论文

共 50 条

[21] Nivolumab/pembrolizumabPeripheral neuropathy: case report
Reactions Weekly, 2020, 1808 (1) : 235 - 235
[22] Nivolumab/ipilimumabLymphocytic hypophysitis: case report
Reactions Weekly, 2021, 1867 (1) : 334 - 334
[23] Ipilimumab/nivolumab/pembrolizumabMyocarditis: case report
Reactions Weekly, 2022, 1914 (1) : 266 - 266
[24] Nivolumab/pembrolizumabMyasthenia gravis: case report
Reactions Weekly, 2019, 1751 (1) : 300 - 300
[25] Nivolumab/pembrolizumabThrombocytopenia and anaphylaxis: case report
Reactions Weekly, 2018, 1683 (1) : 525 - 525
[26] Nivolumab/prednisoneCytomegalovirus enterocolitis: case report
Reactions Weekly, 2022, 1893 (1) : 267 - 267
[27] Nivolumab/relatlimabVarious toxicities: case report
Reactions Weekly, 2024, 2021 (1) : 429 - 429
[28] Ipilimumab/nivolumab/pembrolizumabHypopituitarism: case report
Reactions Weekly, 2021, 1882 (1) : 256 - 256
[29] Nivolumab/sorafenibVarious toxicities: case report
Reactions Weekly, 2020, 1785 (1) : 397 - 397
[30] Nivolumab/pembrolizumabALT increased: case report
Reactions Weekly, 2018, 1704 (1) : 283 - 283

← 1 2 3 4 5 →